Logo

Product Inquiry

Make a product inquiry request

Have a question about clonoSEQ®? Fill out the form below

    Please confirm that you agree you are requesting medical information and certify that you are a physician or healthcare provider, that you are not including any Protected Health Information (PHI), and that the terms of the Adaptive Online Privacy Policy, Terms of Use, HIPAA Notice, and any other Adaptive policies apply.

    Please confirm that you agree you are requesting information and certify that you are a physician or healthcare provider, that you are not including any Protected Health Information (PHI), and that the terms Adaptive Online Privacy Policy, Terms of Use, HIPAA Notice, and any other Adaptive policies apply.

    Questions about a patient report or clonoSEQ results?

    Contact our Clinical Services team at 1 (888) 552-8988.

    Questions about the Adaptive Assist™ Patient Support program or billing?

    Call 1 (855) 236-9230, Monday through Thursday from 9 AM to 7 PM and Friday 9 AM to 5 PM ET.


    This page is intended for a US-based audience.

    clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). CLL Clonality (ID) Tests will also produce an IGHV status result, which is provided as a CLIA-validated laboratory developed test (LDT) but which has not been cleared or approved by the FDA. Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated LDT. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.